Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc. on September 14, 2021, reporting events occurring on September 12, 2021. The filing serves as a Regulation FD disclosure regarding a corporate presentation made by senior management at the H.C. Wainwright 23rd Annual Global Investment Conference held from September 13-15, 2021.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation event rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this specific filing. The document solely announces the availability of a webcast and slide presentation.
Guidance, Outlook, and Risks
Management commentary, guidance, and risk factors are contained within the attached Exhibit 99.1 (Corporate Presentation), which is incorporated by reference. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities under such section.
Key Facts for Investor Verification
- Verify the content of the corporate presentation (Exhibit 99.1) for specific business updates, as the 8-K text only references its existence.
- Note that the presentation materials are not legally "filed" under Section 18 of the Exchange Act, limiting liability protections for the information contained therein.
- Confirm the leadership status, as the report was signed by James Martin, holding the titles of Chief Financial Officer and Co-Interim Chief Executive Officer.
- Check the company's website for the webcast of the presentation scheduled for September 13, 2021.